source
- Hims & Hers pivots to branded GLP-1 drugs after striking deal with Eli LillyHims & Hers, which previously emphasized personalized care through compounded products, is changing its business model. The company is now focusing on established brand-name GLP-1 treatments rathe…
- Beam Therapeutics reports successful pivotal trial of base editing sickle cell therapyBeam Therapeutics announced that its base editing treatment, ristoglogene autogetemcel (risto‑cel), met its primary goal in a pivotal trial for sickle cell disease. The trial showed the therapy cou…